Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy

Zahraa Al-Hilli, Grace Choong, Michael G. Keeney, Daniel W Visscher, James N. Ingle, Matthew Philip Goetz, James W Jakub

Research output: Contribution to journalArticle

Abstract

Objective: Metaplastic breast cancer (MetaBC) is a rare breast cancer subtype poorly responsive to systemic therapy in the metastatic setting with high recurrence rates in the adjuvant setting. However, limited data exist regarding response to neoadjuvant chemotherapy (NAC). We performed a single institutional study to assess the clinical and pathological complete response rates (pCR) of MetaBC to NAC. Methods: Mayo Clinic Rochester patients with MetaBC treated with NAC were identified using the institutional medical index. Patient demographics, tumor characteristics, chemotherapy treatment, clinical and pathological response, and long-term outcomes were reviewed. Pathologic response was assessed by direct pathology review (n = 14) or review of outside surgical and pathology reports (n = 4). Results: Women with MetaBC (n = 18) received NAC from January 1991 to June 2014. The mean age was 50 years (range 33–79) with a mean tumor size of 5.1 cm (range 2.3–11 cm) and 6/18 had pathologically confirmed lymph nodes prior to surgery. The majority (13/18; 72%) were estrogen receptor (ER), progesterone receptor (PR) and HER-2 negative (TNBC), and 1/18 (5.5%) was HER-2 positive. Five had BRCA testing and 2/5 were BRCA-2 positive. The chemotherapy regimens included anthracycline/cyclophosphamide (AC) (n = 1), AC/taxane (n = 3), AC/taxane/platinum (n = 8), taxane/platinum-based regimens (n = 4), taxane/cyclophosphamide (n = 1) and taxane/trastuzumab (n = 1). Five of 18 (28%) progressed on initial treatment including two who developed metastatic disease during NAC. The overall pCR rate was 2/18 (11%). Conclusion: MetaBC is poorly responsive to NAC, with a pCR rate (11%), that is lower than expected in a predominantly TNBC cohort. MetaBC patients should be considered for clinical trials testing new NAC regimens and in the absence of clinical trial enrollment, MetaBC patients with resectable disease should proceed directly to definitive operative management.

Original languageEnglish (US)
Pages (from-to)709-716
Number of pages8
JournalBreast Cancer Research and Treatment
Volume176
Issue number3
DOIs
StatePublished - Aug 15 2019

Fingerprint

Neoadjuvant Therapy
Breast Neoplasms
Drug Therapy
Cyclophosphamide
Anthracyclines
Platinum
Clinical Trials
Surgical Pathology
Progesterone Receptors
Estrogen Receptors
Neoplasms
Therapeutics
Lymph Nodes
Demography
taxane
Pathology
Recurrence

Keywords

  • Metaplastic breast cancer
  • Neoadjuvant chemotherapy
  • Pathological and clinical outcomes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy. / Al-Hilli, Zahraa; Choong, Grace; Keeney, Michael G.; Visscher, Daniel W; Ingle, James N.; Goetz, Matthew Philip; Jakub, James W.

In: Breast Cancer Research and Treatment, Vol. 176, No. 3, 15.08.2019, p. 709-716.

Research output: Contribution to journalArticle

Al-Hilli, Zahraa ; Choong, Grace ; Keeney, Michael G. ; Visscher, Daniel W ; Ingle, James N. ; Goetz, Matthew Philip ; Jakub, James W. / Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy. In: Breast Cancer Research and Treatment. 2019 ; Vol. 176, No. 3. pp. 709-716.
@article{1668485104624dc3b6351f7d35599528,
title = "Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy",
abstract = "Objective: Metaplastic breast cancer (MetaBC) is a rare breast cancer subtype poorly responsive to systemic therapy in the metastatic setting with high recurrence rates in the adjuvant setting. However, limited data exist regarding response to neoadjuvant chemotherapy (NAC). We performed a single institutional study to assess the clinical and pathological complete response rates (pCR) of MetaBC to NAC. Methods: Mayo Clinic Rochester patients with MetaBC treated with NAC were identified using the institutional medical index. Patient demographics, tumor characteristics, chemotherapy treatment, clinical and pathological response, and long-term outcomes were reviewed. Pathologic response was assessed by direct pathology review (n = 14) or review of outside surgical and pathology reports (n = 4). Results: Women with MetaBC (n = 18) received NAC from January 1991 to June 2014. The mean age was 50 years (range 33–79) with a mean tumor size of 5.1 cm (range 2.3–11 cm) and 6/18 had pathologically confirmed lymph nodes prior to surgery. The majority (13/18; 72{\%}) were estrogen receptor (ER), progesterone receptor (PR) and HER-2 negative (TNBC), and 1/18 (5.5{\%}) was HER-2 positive. Five had BRCA testing and 2/5 were BRCA-2 positive. The chemotherapy regimens included anthracycline/cyclophosphamide (AC) (n = 1), AC/taxane (n = 3), AC/taxane/platinum (n = 8), taxane/platinum-based regimens (n = 4), taxane/cyclophosphamide (n = 1) and taxane/trastuzumab (n = 1). Five of 18 (28{\%}) progressed on initial treatment including two who developed metastatic disease during NAC. The overall pCR rate was 2/18 (11{\%}). Conclusion: MetaBC is poorly responsive to NAC, with a pCR rate (11{\%}), that is lower than expected in a predominantly TNBC cohort. MetaBC patients should be considered for clinical trials testing new NAC regimens and in the absence of clinical trial enrollment, MetaBC patients with resectable disease should proceed directly to definitive operative management.",
keywords = "Metaplastic breast cancer, Neoadjuvant chemotherapy, Pathological and clinical outcomes",
author = "Zahraa Al-Hilli and Grace Choong and Keeney, {Michael G.} and Visscher, {Daniel W} and Ingle, {James N.} and Goetz, {Matthew Philip} and Jakub, {James W}",
year = "2019",
month = "8",
day = "15",
doi = "10.1007/s10549-019-05264-2",
language = "English (US)",
volume = "176",
pages = "709--716",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy

AU - Al-Hilli, Zahraa

AU - Choong, Grace

AU - Keeney, Michael G.

AU - Visscher, Daniel W

AU - Ingle, James N.

AU - Goetz, Matthew Philip

AU - Jakub, James W

PY - 2019/8/15

Y1 - 2019/8/15

N2 - Objective: Metaplastic breast cancer (MetaBC) is a rare breast cancer subtype poorly responsive to systemic therapy in the metastatic setting with high recurrence rates in the adjuvant setting. However, limited data exist regarding response to neoadjuvant chemotherapy (NAC). We performed a single institutional study to assess the clinical and pathological complete response rates (pCR) of MetaBC to NAC. Methods: Mayo Clinic Rochester patients with MetaBC treated with NAC were identified using the institutional medical index. Patient demographics, tumor characteristics, chemotherapy treatment, clinical and pathological response, and long-term outcomes were reviewed. Pathologic response was assessed by direct pathology review (n = 14) or review of outside surgical and pathology reports (n = 4). Results: Women with MetaBC (n = 18) received NAC from January 1991 to June 2014. The mean age was 50 years (range 33–79) with a mean tumor size of 5.1 cm (range 2.3–11 cm) and 6/18 had pathologically confirmed lymph nodes prior to surgery. The majority (13/18; 72%) were estrogen receptor (ER), progesterone receptor (PR) and HER-2 negative (TNBC), and 1/18 (5.5%) was HER-2 positive. Five had BRCA testing and 2/5 were BRCA-2 positive. The chemotherapy regimens included anthracycline/cyclophosphamide (AC) (n = 1), AC/taxane (n = 3), AC/taxane/platinum (n = 8), taxane/platinum-based regimens (n = 4), taxane/cyclophosphamide (n = 1) and taxane/trastuzumab (n = 1). Five of 18 (28%) progressed on initial treatment including two who developed metastatic disease during NAC. The overall pCR rate was 2/18 (11%). Conclusion: MetaBC is poorly responsive to NAC, with a pCR rate (11%), that is lower than expected in a predominantly TNBC cohort. MetaBC patients should be considered for clinical trials testing new NAC regimens and in the absence of clinical trial enrollment, MetaBC patients with resectable disease should proceed directly to definitive operative management.

AB - Objective: Metaplastic breast cancer (MetaBC) is a rare breast cancer subtype poorly responsive to systemic therapy in the metastatic setting with high recurrence rates in the adjuvant setting. However, limited data exist regarding response to neoadjuvant chemotherapy (NAC). We performed a single institutional study to assess the clinical and pathological complete response rates (pCR) of MetaBC to NAC. Methods: Mayo Clinic Rochester patients with MetaBC treated with NAC were identified using the institutional medical index. Patient demographics, tumor characteristics, chemotherapy treatment, clinical and pathological response, and long-term outcomes were reviewed. Pathologic response was assessed by direct pathology review (n = 14) or review of outside surgical and pathology reports (n = 4). Results: Women with MetaBC (n = 18) received NAC from January 1991 to June 2014. The mean age was 50 years (range 33–79) with a mean tumor size of 5.1 cm (range 2.3–11 cm) and 6/18 had pathologically confirmed lymph nodes prior to surgery. The majority (13/18; 72%) were estrogen receptor (ER), progesterone receptor (PR) and HER-2 negative (TNBC), and 1/18 (5.5%) was HER-2 positive. Five had BRCA testing and 2/5 were BRCA-2 positive. The chemotherapy regimens included anthracycline/cyclophosphamide (AC) (n = 1), AC/taxane (n = 3), AC/taxane/platinum (n = 8), taxane/platinum-based regimens (n = 4), taxane/cyclophosphamide (n = 1) and taxane/trastuzumab (n = 1). Five of 18 (28%) progressed on initial treatment including two who developed metastatic disease during NAC. The overall pCR rate was 2/18 (11%). Conclusion: MetaBC is poorly responsive to NAC, with a pCR rate (11%), that is lower than expected in a predominantly TNBC cohort. MetaBC patients should be considered for clinical trials testing new NAC regimens and in the absence of clinical trial enrollment, MetaBC patients with resectable disease should proceed directly to definitive operative management.

KW - Metaplastic breast cancer

KW - Neoadjuvant chemotherapy

KW - Pathological and clinical outcomes

UR - http://www.scopus.com/inward/record.url?scp=85066885749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066885749&partnerID=8YFLogxK

U2 - 10.1007/s10549-019-05264-2

DO - 10.1007/s10549-019-05264-2

M3 - Article

VL - 176

SP - 709

EP - 716

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -